This is a narrative-driven IP filing with no financial or clinical data to support a re-rating. Monitor for future preclinical data releases or partnership announcements related to the Nectin-4 x PD-L1 backbone, but the stock is unlikely to move materially on this news alone given the early stage and lack of concrete catalysts.
Price Chart
Executive Summary
Aptevo Therapeutics announced a new solid tumor strategy and filed a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone. The press release describes the platform's potential for radiopharmaceuticals, T-cell engagers, and other immune-based approaches, but provides no financial data, clinical data, or concrete partnership agreements. This is an early-stage, non-financial strategic update for a clinical-stage biotech with a $5M market cap, representing a modest IP and pipeline narrative event with no immediate revenue or catalyst impact.
Key Facts
- Aptevo filed a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone.
- The backbone is designed to support multiple therapeutic approaches including radiopharmaceuticals, T-cell engagers, and immune-modulating therapies.
- The filing is part of a new solid tumor strategy announced on July 27, 2026.
- Aptevo's lead clinical candidate, mipletamig, is being evaluated in frontline acute myeloid leukemia.
- The company is a clinical-stage biotechnology company with a market cap of $5M and no revenue data provided in this filing.
Financial Impact
No financial figures disclosed in the filing. The patent filing is a non-financial event with no immediate revenue or cost impact.
Risk Factors
- Patent application may not result in an issued patent or adequate protection.
- Preclinical and clinical development of the backbone is early-stage and carries high failure risk.
- No financial data or guidance was provided; the company's cash runway and burn rate remain unknown from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-318056 |
| Document: apvo-ex99_1.htm | 0001193125-26-318056 |
| Document: 0001193125-26-318056-index-headers.html | 0001193125-26-318056 |
| Document: 0001193125-26-318056-index.html | 0001193125-26-318056 |
| Document: 0001193125-26-318056.txt | 0001193125-26-318056 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $1.50 | awaiting T+5 | — | $1.28 (−14.67%) |
Oct 23, 2026 4d ago | 8-K | $1.50 | awaiting T+5 | — | $1.28 (−14.67%) |
Oct 14, 2026 13d ago | 8-K | $1.73 $1.60 | ▼ −7.51% | ▼ −7.97% | $1.28 (−26.01%) |
Sep 24, 2026 4w ago | 8-K | $1.83 $1.76 | ▼ −3.83% | ▼ −3.41% | $1.28 (−30.05%) |
Sep 3, 2026 7w ago | 424B4 / 8-K | $1.71 $1.82 | ▲ +6.43% | ▲ +7.58% | $1.28 (−25.15%) |
Sep 3, 2026 7w ago | EFFECT | $1.71 $1.82 | ▼ −6.43% | ▼ −7.58% | $1.28 (+25.15%) |
Aug 14, 2026 10w ago | 8-K | $2.94 $2.68 | ▼ −8.84% | ▼ −7.48% | $1.28 (−56.46%) |
Jul 27, 2026 13w ago | 8-K | $4.21 $3.95 | ▼ −6.18% | ▼ −8.44% | $1.28 (−69.60%) |
Jun 30, 2026 17w ago | 8-K | $4.45 $4.51 | ▲ +1.35% | ▲ +1.09% | $1.28 (−71.24%) |
May 6, 2026 24w ago | 8-K | $4.86 $4.76 | ▼ −2.06% | ▼ −3.56% | $1.28 (−73.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers